Comparison
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190 vs 13q12 3 Microdeletion Syndrome C4750951
Clinical comparison between 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial and 13q12 3 Microdeletion Syndrome for differential diagnosis and treatment planning.
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
A partial form of enzyme deficiency affecting hormone production. Symptoms vary but may include hormonal imbalances and elevated blood pressure. Treatment usually involves hormone replacement and regular medical follow-up.
13q12 3 Microdeletion Syndrome C4750951
A rare genetic condition where a small piece of chromosome 13 is missing. It can cause various developmental and medical concerns. Care is supportive and tailored to the individual's needs.
6 comparison axes
Onset
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
Variable
13q12 3 Microdeletion Syndrome C4750951
0-null
Onset patterns differ
Severity
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
severe
13q12 3 Microdeletion Syndrome C4750951
moderate
Different severity levels
Chronic
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
Chronic
13q12 3 Microdeletion Syndrome C4750951
Chronic
Differing course
Communicable
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
No
13q12 3 Microdeletion Syndrome C4750951
No
Different transmission
Body System
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
endocrine
13q12 3 Microdeletion Syndrome C4750951
congenital
Same/different system
Category
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
endocrine
13q12 3 Microdeletion Syndrome C4750951
genetic
Different category
Bottom line
17-alpha-hydroxylase-17-20-lyase-deficiency-combined-partial-C4017190 and 13q12-3-microdeletion-syndrome-C4750951 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190 | 13q12 3 Microdeletion Syndrome C4750951 | Discriminating power |
|---|---|---|---|
| Blood pressure | Hypertension may occur from mineralocorticoid-related imbalance; severity is variable. | Hypertension is not an established core feature from the supplied description. | Moderate |
| Development | Primary presentation is endocrine rather than a defined developmental syndrome. | Developmental and other medical concerns may occur and vary by person. | High |
| Sexual development | Sex-steroid production may be reduced, with variable puberty or genital findings. | Specific genital or pubertal findings are not established by the supplied source. | Moderate |
When to favor each condition
Choose 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190 when
Hypertension with suspected steroid imbalance
The enzyme deficiency directly affects adrenal and gonadal hormone pathways.
Moderate
Abnormal puberty or sex-steroid pattern
Partial 17-alpha-hydroxylase/17,20-lyase deficiency can impair sex-steroid synthesis.
Moderate
Endocrine evaluation without syndromic features
An endocrine category fits better than a chromosomal microdeletion when development is not the main concern.
Low
Choose 13q12 3 Microdeletion Syndrome C4750951 when
Congenital or developmental concerns
The microdeletion is a genetic condition whose care is individualized and supportive.
Moderate
Suspected chromosomal copy-number change
A missing segment at 13q12.3 is identified by genetic testing, not hormone assays alone.
High
Multiple unexplained congenital findings
A chromosomal evaluation may be appropriate, but this comparison cannot confirm the syndrome.
Low
How key tests differ
| Test | 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190 | 13q12 3 Microdeletion Syndrome C4750951 | Interpretation |
|---|---|---|---|
| Steroid hormone profile | May show pathway-related hormonal imbalance; exact cutoffs are not supplied. | No characteristic steroid pattern is established here. | An abnormal profile supports endocrine evaluation but is not itself a diagnosis. |
| Chromosomal microarray | Not expected to identify this enzyme deficiency. | May detect a 13q12.3 deletion when present. | Genetic confirmation requires qualified laboratory and clinician interpretation. |
| Blood pressure monitoring | Elevated readings may be relevant and should be tracked. | No specific blood-pressure pattern is established. | Measurements guide care but do not distinguish the conditions alone. |
Prognosis comparison
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
- Outcome
- Often a chronic endocrine condition; outcome depends on hormonal control and complications, which are not quantified here.
- Factors
- Blood pressure, hormone balance, puberty or fertility needs, and adherence to follow-up.
13q12 3 Microdeletion Syndrome C4750951
- Outcome
- Usually a lifelong genetic condition with variable developmental and medical needs.
- Factors
- Deletion effects, associated anomalies, developmental support, and individual health problems.
Time frame: Both are generally long-term; onset may be variable for the enzyme deficiency and congenital for the microdeletion.
No reliable mortality or quality comparison can be made from the supplied data.
Complications comparison
| Complication | Presentation |
|---|---|
| Hypertension-related effects | Possible when blood pressure is persistently high; complications are not quantified here. Not established as a typical complication from the source. Clinicians should assess cardiovascular risk individually. |
| Hormone deficiency effects | May include puberty, fertility, or electrolyte concerns depending on severity. Not a defining endocrine complication in the supplied description. Replacement decisions require specialist supervision; no dose is implied. |
| Developmental disability | Not described as a core feature. Developmental concerns may occur, with wide individual variation. Supportive therapies should match assessed needs. |
Patient education highlights
- HighDifferent causes
One condition involves hormone-producing enzyme function; the other involves missing chromosomal material.
- HighFollow-up
Both generally need ongoing, individualized medical care rather than a one-time test interpretation.
- MediumLimits of information
Sparse source data do not establish exact symptoms, prevalence, outcomes, or treatment doses.